| scholarly article | Q13442814 |
| P50 | author | Bruce R Ksander | Q87852809 |
| P2093 | author name string | Suzanne Ostrand-Rosenberg | |
| Minu K Srivastava | |||
| Samuel T Haile | |||
| Jacobus J Bosch | |||
| Sabine Britting | |||
| Annette M Zeender | |||
| Julie B Wolf | |||
| Nnenna I Agu | |||
| Preethi Somasundaram | |||
| P2860 | cites work | Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production | Q24292957 |
| MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes | Q24644382 | ||
| Myeloid-derived suppressor cells as regulators of the immune system | Q28131637 | ||
| Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion | Q28131654 | ||
| Expression of programmed death 1 ligands by murine T cells and APC | Q28214264 | ||
| A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames | Q28284379 | ||
| CD80 cytoplasmic domain controls localization of CD28, CTLA-4, and protein kinase Ctheta in the immunological synapse | Q30478206 | ||
| The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time | Q33546133 | ||
| Cell-based vaccines for the stimulation of immunity to metastatic cancers | Q33776134 | ||
| Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners | Q33945653 | ||
| Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. | Q34055865 | ||
| B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance | Q34122678 | ||
| Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). | Q34484749 | ||
| Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity | Q34554995 | ||
| Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses | Q34650346 | ||
| Interaction of human PD-L1 and B7-1. | Q34789854 | ||
| Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity | Q35762422 | ||
| Regulatory T cells, tumour immunity and immunotherapy | Q36430144 | ||
| B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells | Q36508914 | ||
| Activation and differentiation requirements of primary T cells in vitro | Q36566049 | ||
| Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines | Q36922798 | ||
| PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells | Q36986702 | ||
| PDL-1 upregulation on monocytes and T cells by HIV via type I interferon: restricted expression of type I interferon receptor by CCR5-expressing leukocytes | Q37408390 | ||
| Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells. | Q39832869 | ||
| The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes. | Q40088629 | ||
| MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells | Q40136451 | ||
| B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma | Q40626031 | ||
| Subcellular localization of CD80 receptors is dependent on an intact cytoplasmic tail and is required for CD28-dependent T cell costimulation. | Q41158763 | ||
| Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma). | Q41360601 | ||
| Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line | Q41699259 | ||
| Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells | Q42114592 | ||
| Upregulation of PD-L1 on monocytes and dendritic cells by HIV-1 derived TLR ligands | Q42932292 | ||
| A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer | Q42940016 | ||
| CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. | Q45092706 | ||
| Essential role of dendritic cell CD80/CD86 costimulation in the induction, but not reactivation, of TH2 effector responses in a mouse model of asthma | Q47229710 | ||
| Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. | Q48009892 | ||
| Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. | Q50777089 | ||
| B7-H1 up-regulation on dendritic-like leukemia cells suppresses T cell immune function through modulation of IL-10/IL-12 production and generation of Treg cells. | Q51808283 | ||
| Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. | Q52826622 | ||
| A novel phenotype for an activated macrophage: the type 2 activated macrophage. | Q52940996 | ||
| The MCF10 family of spontaneously immortalized human breast epithelial cell lines: models of neoplastic progression. | Q53477584 | ||
| IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis | Q54285337 | ||
| PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation. | Q54515974 | ||
| Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro | Q56902028 | ||
| Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production | Q56907534 | ||
| Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors | Q56909582 | ||
| Transmembrane signaling through CD80 (B7-1) induces growth arrest and cell spreading of human B lymphocytes accompanied by protein tyrosine phosphorylation | Q71503485 | ||
| Signal transduction by B7/BB1 expressed on activated T lymphocytes: cross-linking of B7/BB1 induces protein tyrosine phosphorylation and synergizes with signalling through T-cell receptor/CD3 | Q71565255 | ||
| Melanomas that develop within the eye inhibit lymphocyte proliferation | Q73923165 | ||
| Two regions in the CD80 cytoplasmic tail regulate CD80 redistribution and T cell costimulation | Q77319204 | ||
| Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain | Q82310347 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 6822-6829 | |
| P577 | publication date | 2011-05-09 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80 | |
| P478 | volume | 186 |
| Q42232179 | A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation |
| Q54204422 | A transgenic mouse model for HLA-B*57:01-linked abacavir drug tolerance and reactivity. |
| Q35016870 | B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells |
| Q41708676 | CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1+ tumor cells, and extends the survival of tumor-bearing humanized mice |
| Q64064545 | Characterization of CD4+ T cells primed and boosted by MHCII primary uveal melanoma cell-based vaccines |
| Q54252192 | Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model. |
| Q39313794 | Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease. |
| Q50921102 | Control of Immune Response to Allogeneic Embryonic Stem Cells by CD3 Antibody-Mediated Operational Tolerance Induction. |
| Q93382101 | Efficacy of different hemodialysis methods on dendritic cell marker CD40 and CD80 and platelet activation marker CD62P and P10 in patients with chronic renal failure |
| Q47248817 | Emerging trends in the immunotherapy of pancreatic cancer. |
| Q37521861 | Enhanced function of cytotoxic T lymphocytes induced by dendritic cells modified with truncated PSMA and 4-1BBL. |
| Q64979269 | Epithelial CD80 promotes immune surveillance of colonic preneoplastic lesions and its expression is increased by oxidative stress through STAT3 in colon cancer cells. |
| Q33275611 | Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma |
| Q40073193 | Granulocytic myeloid-derived suppressor cells suppress virus-specific CD8+ T cell responses during acute Friend retrovirus infection |
| Q42281477 | Impact of the prolymphangiogenic crosstalk in the tumor microenvironment on lymphatic cancer metastasis. |
| Q36615048 | Inflammation in uveal melanoma |
| Q36021225 | Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells |
| Q42200330 | Ocular immune privilege and ocular melanoma: parallel universes or immunological plagiarism? |
| Q56890523 | PD-L1 Binds to B7-1 Only on the Same Cell Surface |
| Q52714354 | PD-L1 expression in medulloblastoma: an evaluation by subgroup. |
| Q33569771 | PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation |
| Q38685359 | PD-L1-specific T cells. |
| Q36269232 | Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance |
| Q37696391 | Placental immune editing switch (PIES): learning about immunomodulatory pathways from a unique case report. |
| Q33848154 | Programmed cell death ligand 1 expression in osteosarcoma |
| Q36141581 | Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients |
| Q64084861 | Radiotherapy Both Promotes and Inhibits Myeloid-Derived Suppressor Cell Function: Novel Strategies for Preventing the Tumor-Protective Effects of Radiotherapy |
| Q46871198 | Relationship Between PD-L1 Expression and Clinical Characteristics in Patients with Breast Invasive Ductal Carcinoma |
| Q99571808 | Revisiting the PD-1 pathway |
| Q47419476 | Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes |
| Q39114787 | Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression |
| Q92778969 | T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity |
| Q34626229 | The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on melanoma-driven CD8+ T cell exhaustion |
| Q26829847 | The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity |
| Q37922793 | Therapeutic targeting of B7-H1 in breast cancer. |
| Q41964740 | Type Iγ phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-κB. |
Search more.